Meftal%25252525252525252525252525252525252525252520spas

# Meftal-Spas ## Overview Meftal-Spas is a fixed-dose combination medication containing **Mefenamic Acid** (250 mg), an NSAID, and **Dicyclomine Hydrochloride** (10 mg), an antispasmodic/anticholinergic agent. It is designed to provide dual relief from smooth muscle spasms and prostaglandin-mediated pain. ## Primary Indications * Management of spasmodic dysmenorrhea (primary). * Functional bowel/GI disorders characterized by hypermotility and cramping. * Musculoskeletal pain associated with smooth muscle spasm. ## Adult Dosing * **Standard Dose:** 1 tablet (250 mg Mefenamic Acid / 10 mg Dicyclomine) taken 3 to 4 times daily. * **Maximum Dose:** Do not exceed 4 tablets in 24 hours. * **Duration:** Use for the shortest duration necessary; generally not recommended for more than 7 days. ## Pediatric Dosing * **Children < 12 years:** Generally not recommended due to lack of established safety and efficacy data for this specific fixed-dose combination. * **Adolescents (12+ years):** Same as adult dosing, though weight-based adjustment is preferred if possible. Use with caution. ## Dose Adjustments * **Renal Impairment:** Avoid or exercise extreme caution in patients with creatinine clearance < 30 mL/min due to the Mefenamic Acid component. * **Hepatic Impairment:** Use with caution; monitor for potential hepatotoxicity. * **Geriatric Patients:** Increased susceptibility to anticholinergic side effects (e.g., urinary retention, confusion, constipation). Use the lowest effective dose. ## Contraindications * Known hypersensitivity to Mefenamic Acid, Dicyclomine, or aspirin/NSAIDs. * History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. * Active peptic ulceration or inflammatory bowel disease (ulcerative colitis). * Obstructive uropathy, obstructive GI disease, or severe ulcerative colitis. * Myasthenia gravis. * Coronary artery bypass graft (CABG) surgery (perioperative period). ## Adverse Effects * **NSAID-related:** Epigastric pain, GI hemorrhage, peptic ulcer, elevated liver enzymes, fluid retention, and increased risk of cardiovascular events (MI/stroke). * **Anticholinergic-related:** Dry mouth, blurred vision, dizziness, tachycardia, urinary hesitancy, and constipation. ## Key Drug Interactions * **Anticoagulants (e.g., Warfarin):** Increases risk of bleeding. * **Corticosteroids/SSRIs:** Increases risk of GI ulceration. * **Antihypertensives/Diuretics:** NSAIDs may reduce the natriuretic effect and decrease antihypertensive efficacy. * **Other Anticholinergics:** Synergistic effects (increased risk of confusion and urinary retention). * **Lithium/Methotrexate:** NSAIDs may increase plasma concentrations and toxicity. ## Monitoring * Monitor blood pressure periodically. * Monitor for signs of GI bleeding (melena, hematemesis). * Monitor renal function (BUN/SCr) in long-term elderly users. * Assess for mental status changes in geriatric patients (anticholinergic burden). ## Clinical Pearls * Take with food or milk to minimize gastric irritation from the Mefenamic Acid. * Patients should be cautioned against operating heavy machinery until the effect of the Dicyclomine (drowsiness/blurred vision) is known. * Dicyclomine can decrease sweating; advise patients to avoid overheating or heavy exercise in hot environments. * **Uncertainty Note:** Specific dosing protocols may vary by regional clinical guidelines; always confirm with local institutional formulary or pediatric specialist guidance before prescribing for children. *** **Disclaimer:** This information is for educational purposes only. Always verify current prescribing information, contraindications, and drug interactions via a reliable, updated clinical database (e.g., Lexicomp, UpToDate, or the official manufacturer’s product circular) before prescribing or administering any medication.